title: Safety of intracoronary administration of c-myc antisense oligomers after percutaneous transluminal coronary angioplasty (PTCA).
abstract: We wished to assess the clinical safety and pharmacokinetics of ascending doses of a synthetic oligodeoxynucleotide (LR-3280) administered after coronary angioplasty. Antisense oligodeoxynucleotides designed to hybridize with target messenger ribonucleic acid (mRNA) in a complementary fashion to inhibit the expression of corresponding protein also have the ability to bind to extracellular growth factors. LR-3280 has been shown to reduce c-myc expression, inhibit growth and collagen biosynthesis in human vascular cells, and reduce neointimal formation in animal models of vascular injury. After successful percutaneous transluminal coronary angioplasty (PTCA), 78 patients were randomized to receive either standard care (n = 26) or standard care and escalating doses of LR-3280 (n = 52) (doses from 1 to 24 mg), administered into target vessel through a guiding catheter. Overall safety was evaluated by clinical adverse events, laboratory tests, and electrocardiograms. Patency was evaluated by quantitative coronary angiography. There were no clinically significant differences between treated and control patients. No adverse effects of LR-3280 on the patency of dilated coronary arteries were observed. Pharmacokinetic data revealed that peak plasma concentrations of LR-3280 occurred at 1 minute over the studied dose range and rapidly decreased after approximately1 hour, with little LR-3280 detected in the urine between 0-6 hours and 12-24 hours. The intracoronary administration of LR-3280 is well tolerated at doses up to 24 mg and produces no adverse effects in dilated coronary arteries. These results provide the basis for the evaluation of local delivery of this phosphorothioate oligodeoxynucleotide for the prevention of human vasculoproliferative disease.
authors.affiliation: Clinica Olivos, Cardiovascular Department, Buenos Aires, Republica Argentina. froque@arnet.com.ar
authors.forename: F
authors.initials: F
authors.lastname: Roqué
authors.forename: G
authors.initials: G
authors.lastname: Mon
authors.forename: J
authors.initials: J
authors.lastname: Belardi
authors.forename: A
authors.initials: A
authors.lastname: Rodriguez
authors.forename: L
authors.initials: L
authors.lastname: Grinfeld
authors.forename: R
authors.initials: R
authors.lastname: Long
authors.forename: S
authors.initials: S
authors.lastname: Grossman
authors.forename: A
authors.initials: A
authors.lastname: Malcolm
authors.forename: G
authors.initials: G
authors.lastname: Zon
authors.forename: M L
authors.initials: ML
authors.lastname: Ormont
authors.forename: D L
authors.initials: DL
authors.lastname: Fischman
authors.forename: Y
authors.initials: Y
authors.lastname: Shi
authors.forename: A
authors.initials: A
authors.lastname: Zalewski
mesh_terms: D000368:Aged; D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects*; D003327:Coronary Disease / Q000517:prevention & control*; D005260:Female; D006801:Humans; D007269:Injections, Intra-Arterial; D008297:Male; D008875:Middle Aged; D009841:Oligonucleotides / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D012449:Safety
chemical_list: C434123:LR-3280; D009841:Oligonucleotides